Company intelligence / Profile preview

Lotus Rx

Ownership: Private
Development stage: Commercial

Overview

Lotus Pharmaceutical is a leading specialty generic pharmaceutical company headquartered in Taiwan. It focuses on high-quality, difficult-to-make generics and novel pharmaceuticals across Asia and globally. The company boasts a robust R&D/manufacturing platform with over $500 million annual revenue as of recent years. Recent clinical/commercial highlights include an exclusive licensing deal for LNZ100 (aceclidine-based eye drop for presbyopia) covering Korea and Southeast Asia; FDA review for LNZ100 expected August 2025[3][5].

Modalities: Small molecule
Industry: Biotech

Partnerships

LENZ Therapeutics – exclusive license/commercialization agreement for LNZ100 in Korea/Southeast Asia ($125M+ milestone/royalty deal)[3][5].

Beyond the preview

Go deeper on Lotus Rx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lotus Rx.

Explore the full profile